Preliminary results of the TACTI-002 phase II study on the use of efti plus pembrolizumab in the second-line treatment of patients with unselected HNSCC PD-L1 metastases are promising and indicate that the ORR and DCR are 39% and 50%, respectively. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.